Int Arch Allergy Immunol:鼻内喷洒精油对持久过敏性鼻炎患者的影响:一项前瞻性研究

2020-10-29 AlexYang MedSci原创

在过敏性鼻炎(AR)的症状中,鼻阻塞尤其影响生活质量。抗组胺药和鼻内皮质激素是最常见的对症药物,但其疗效往往不全面。精油(EO)在治疗AR患者中表现出了抗炎的作用和潜力。最近,有研究人员评估了一种基于

在过敏性鼻炎(AR)的症状中,鼻阻塞尤其影响生活质量。抗组胺药和鼻内皮质激素是最常见的对症药物,但其疗效往往不全面。精油(EO)在治疗AR患者中表现出了抗炎的作用和潜力。最近,有研究人员评估了一种基于EO的高渗性鼻腔喷雾剂对常年AR(PAR)症状的有效性情况。

研究是一个前瞻性、开放标签、非随机、多中心试验,包括了43名对螨虫过敏的PAR患者,且未控制一年以上。所有患者均使用Puressentiel?呼吸-消肿剂鼻腔喷雾剂(PRDNS)治疗30天。在研究期间,他们的常规治疗保持不变。治疗前后,每位参与者都填写了一份鼻炎问卷-ARCT。研究人员还测量了鼻腔吸气峰流量(NIPF)。研究发现,D0和D30时ARCT平均值分别为16.4和20.5(P<0.001);D0和D30之间平均增加4.1(P<0.001)。治疗30天后鼻炎得到控制的患者比例为69.8,而治疗前为14%(P<0.001)。D0和D30时平均NIPF分别为86.5 L/min和105.1 L/min(P<0.001);D0和D30之间平均增加18.5 L/min。

PRDNS治疗第0天和第30天AR控制测试(ARCT)的个体和平均值

最后,研究人员指出,基于高渗EO的鼻腔喷雾剂可以作为PAR治疗的一种新选择。当鼻部症状不能完全控制时,也可作为一种补充疗法。

原始出处:

Davide Caimmi , Catherine Neukirch , Renaud Louis et al. Effect of the Use of Intranasal Spray of Essential Oils in Patients with Perennial Allergic Rhinitis: A Prospective Study. Int Arch Allergy Immunol. Sep 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1914482, encodeId=50e0191448208, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jan 09 04:42:59 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047328, encodeId=ae3c204e328ff, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed May 05 22:42:59 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006502, encodeId=e3352006502ca, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu May 13 19:42:59 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329431, encodeId=87ec1329431b9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584589, encodeId=2ff6158458920, content=<a href='/topic/show?id=94d0e645660' target=_blank style='color:#2F92EE;'>#精油#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76456, encryptionId=94d0e645660, topicName=精油)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=537517051731, createdName=ms4657536712156177, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895467, encodeId=56e789546e3c, content=鼻炎治疗新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c585423313, createdName=ms3000000833147554, createdTime=Thu Oct 29 19:15:17 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895411, encodeId=dc38895411c9, content=基于高渗EO的鼻腔喷雾剂可以作为持久过敏性鼻炎PAR治疗的一种新选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211019/df01a4bfb64246379ddfef3370d04115/e1274c8eb5e440918f56f83bcfea9031.jpg, createdBy=3a345397082, createdName=Jessica, createdTime=Thu Oct 29 15:06:24 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895401, encodeId=8f9089540182, content=好文章,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Thu Oct 29 14:00:38 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1914482, encodeId=50e0191448208, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jan 09 04:42:59 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047328, encodeId=ae3c204e328ff, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed May 05 22:42:59 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006502, encodeId=e3352006502ca, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu May 13 19:42:59 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329431, encodeId=87ec1329431b9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584589, encodeId=2ff6158458920, content=<a href='/topic/show?id=94d0e645660' target=_blank style='color:#2F92EE;'>#精油#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76456, encryptionId=94d0e645660, topicName=精油)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=537517051731, createdName=ms4657536712156177, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895467, encodeId=56e789546e3c, content=鼻炎治疗新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c585423313, createdName=ms3000000833147554, createdTime=Thu Oct 29 19:15:17 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895411, encodeId=dc38895411c9, content=基于高渗EO的鼻腔喷雾剂可以作为持久过敏性鼻炎PAR治疗的一种新选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211019/df01a4bfb64246379ddfef3370d04115/e1274c8eb5e440918f56f83bcfea9031.jpg, createdBy=3a345397082, createdName=Jessica, createdTime=Thu Oct 29 15:06:24 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895401, encodeId=8f9089540182, content=好文章,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Thu Oct 29 14:00:38 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1914482, encodeId=50e0191448208, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jan 09 04:42:59 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047328, encodeId=ae3c204e328ff, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed May 05 22:42:59 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006502, encodeId=e3352006502ca, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu May 13 19:42:59 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329431, encodeId=87ec1329431b9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584589, encodeId=2ff6158458920, content=<a href='/topic/show?id=94d0e645660' target=_blank style='color:#2F92EE;'>#精油#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76456, encryptionId=94d0e645660, topicName=精油)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=537517051731, createdName=ms4657536712156177, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895467, encodeId=56e789546e3c, content=鼻炎治疗新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c585423313, createdName=ms3000000833147554, createdTime=Thu Oct 29 19:15:17 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895411, encodeId=dc38895411c9, content=基于高渗EO的鼻腔喷雾剂可以作为持久过敏性鼻炎PAR治疗的一种新选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211019/df01a4bfb64246379ddfef3370d04115/e1274c8eb5e440918f56f83bcfea9031.jpg, createdBy=3a345397082, createdName=Jessica, createdTime=Thu Oct 29 15:06:24 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895401, encodeId=8f9089540182, content=好文章,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Thu Oct 29 14:00:38 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1914482, encodeId=50e0191448208, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jan 09 04:42:59 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047328, encodeId=ae3c204e328ff, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed May 05 22:42:59 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006502, encodeId=e3352006502ca, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu May 13 19:42:59 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329431, encodeId=87ec1329431b9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584589, encodeId=2ff6158458920, content=<a href='/topic/show?id=94d0e645660' target=_blank style='color:#2F92EE;'>#精油#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76456, encryptionId=94d0e645660, topicName=精油)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=537517051731, createdName=ms4657536712156177, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895467, encodeId=56e789546e3c, content=鼻炎治疗新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c585423313, createdName=ms3000000833147554, createdTime=Thu Oct 29 19:15:17 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895411, encodeId=dc38895411c9, content=基于高渗EO的鼻腔喷雾剂可以作为持久过敏性鼻炎PAR治疗的一种新选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211019/df01a4bfb64246379ddfef3370d04115/e1274c8eb5e440918f56f83bcfea9031.jpg, createdBy=3a345397082, createdName=Jessica, createdTime=Thu Oct 29 15:06:24 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895401, encodeId=8f9089540182, content=好文章,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Thu Oct 29 14:00:38 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
    2020-10-31 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=1914482, encodeId=50e0191448208, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jan 09 04:42:59 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047328, encodeId=ae3c204e328ff, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed May 05 22:42:59 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006502, encodeId=e3352006502ca, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu May 13 19:42:59 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329431, encodeId=87ec1329431b9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584589, encodeId=2ff6158458920, content=<a href='/topic/show?id=94d0e645660' target=_blank style='color:#2F92EE;'>#精油#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76456, encryptionId=94d0e645660, topicName=精油)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=537517051731, createdName=ms4657536712156177, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895467, encodeId=56e789546e3c, content=鼻炎治疗新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c585423313, createdName=ms3000000833147554, createdTime=Thu Oct 29 19:15:17 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895411, encodeId=dc38895411c9, content=基于高渗EO的鼻腔喷雾剂可以作为持久过敏性鼻炎PAR治疗的一种新选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211019/df01a4bfb64246379ddfef3370d04115/e1274c8eb5e440918f56f83bcfea9031.jpg, createdBy=3a345397082, createdName=Jessica, createdTime=Thu Oct 29 15:06:24 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895401, encodeId=8f9089540182, content=好文章,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Thu Oct 29 14:00:38 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1914482, encodeId=50e0191448208, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jan 09 04:42:59 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047328, encodeId=ae3c204e328ff, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed May 05 22:42:59 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006502, encodeId=e3352006502ca, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu May 13 19:42:59 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329431, encodeId=87ec1329431b9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584589, encodeId=2ff6158458920, content=<a href='/topic/show?id=94d0e645660' target=_blank style='color:#2F92EE;'>#精油#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76456, encryptionId=94d0e645660, topicName=精油)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=537517051731, createdName=ms4657536712156177, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895467, encodeId=56e789546e3c, content=鼻炎治疗新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c585423313, createdName=ms3000000833147554, createdTime=Thu Oct 29 19:15:17 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895411, encodeId=dc38895411c9, content=基于高渗EO的鼻腔喷雾剂可以作为持久过敏性鼻炎PAR治疗的一种新选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211019/df01a4bfb64246379ddfef3370d04115/e1274c8eb5e440918f56f83bcfea9031.jpg, createdBy=3a345397082, createdName=Jessica, createdTime=Thu Oct 29 15:06:24 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895401, encodeId=8f9089540182, content=好文章,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Thu Oct 29 14:00:38 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
    2020-10-29 ms3000000833147554

    鼻炎治疗新进展

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1914482, encodeId=50e0191448208, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jan 09 04:42:59 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047328, encodeId=ae3c204e328ff, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed May 05 22:42:59 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006502, encodeId=e3352006502ca, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu May 13 19:42:59 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329431, encodeId=87ec1329431b9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584589, encodeId=2ff6158458920, content=<a href='/topic/show?id=94d0e645660' target=_blank style='color:#2F92EE;'>#精油#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76456, encryptionId=94d0e645660, topicName=精油)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=537517051731, createdName=ms4657536712156177, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895467, encodeId=56e789546e3c, content=鼻炎治疗新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c585423313, createdName=ms3000000833147554, createdTime=Thu Oct 29 19:15:17 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895411, encodeId=dc38895411c9, content=基于高渗EO的鼻腔喷雾剂可以作为持久过敏性鼻炎PAR治疗的一种新选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211019/df01a4bfb64246379ddfef3370d04115/e1274c8eb5e440918f56f83bcfea9031.jpg, createdBy=3a345397082, createdName=Jessica, createdTime=Thu Oct 29 15:06:24 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895401, encodeId=8f9089540182, content=好文章,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Thu Oct 29 14:00:38 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
    2020-10-29 Jessica

    基于高渗EO的鼻腔喷雾剂可以作为持久过敏性鼻炎PAR治疗的一种新选择

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1914482, encodeId=50e0191448208, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Jan 09 04:42:59 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047328, encodeId=ae3c204e328ff, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed May 05 22:42:59 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006502, encodeId=e3352006502ca, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu May 13 19:42:59 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329431, encodeId=87ec1329431b9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584589, encodeId=2ff6158458920, content=<a href='/topic/show?id=94d0e645660' target=_blank style='color:#2F92EE;'>#精油#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76456, encryptionId=94d0e645660, topicName=精油)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=537517051731, createdName=ms4657536712156177, createdTime=Sat Oct 31 04:42:59 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895467, encodeId=56e789546e3c, content=鼻炎治疗新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c585423313, createdName=ms3000000833147554, createdTime=Thu Oct 29 19:15:17 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895411, encodeId=dc38895411c9, content=基于高渗EO的鼻腔喷雾剂可以作为持久过敏性鼻炎PAR治疗的一种新选择, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211019/df01a4bfb64246379ddfef3370d04115/e1274c8eb5e440918f56f83bcfea9031.jpg, createdBy=3a345397082, createdName=Jessica, createdTime=Thu Oct 29 15:06:24 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895401, encodeId=8f9089540182, content=好文章,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Thu Oct 29 14:00:38 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
    2020-10-29 yangchou

    好文章,谢谢分享

    0

相关资讯

GUT:肠道细菌长链脂肪酸与抗炎

肠道细菌产生3-羟基十八烯酸是有效的抗炎成分,其生成微生物/宿主相互作用的结果

Dent Mater J:含有表面预处理玻璃璃聚物(S-PRG)填料根管封闭剂的生物学评估

表面预处理的玻璃璃聚物(S-PRG)填料能够释放多种离子,如氟化物、硼酸盐和锶,以释放生物活性效应。研究将S-PRG填料融入根管封闭剂中(S-PRG sealer),随后评估S-PRG封闭剂的抗菌和抗炎效果,并与常规含氧化硅填料的封闭剂(silica sealer)相比较。

Int Immunopharmacol:MicroRNA-345-5p是实验过敏性鼻炎中的一个抗炎症因子

过敏性鼻炎(AR)是一种常见的慢性疾病,主要特征为鼻黏膜上的炎症。MicroRNA(miRNAs)在AR中的作用已经有所阐释,尤其是调控炎症响应中具有作用。最近,有研究人员在AR小鼠中探索了miR-3

Molecules:冬虫夏草菌丝培养提取物(Cs-4)对变应性鼻炎和哮喘模型鼠的抗炎作用

变应性鼻炎和哮喘是呼吸道常见的慢性变应性疾病,伴有IgE介导的炎症和2 型辅助性T细胞、肥大细胞和嗜酸性粒细胞的参与。冬虫夏草是一种寄生在鳞翅目幼虫上的真菌。它被认为是一种促进健康的食物,也是治疗呼吸

真的有抗炎饮食吗?

牙龈肿痛了、扁桃体肿痛了、不小心割破的伤口周围红肿了……这些都是大家很明显能感知到的急性炎症反应,还有一些慢性炎症反应,可能正在体内悄悄的进行着,我们自己毫不知情。那么炎症到底是怎么回事呢?炎症要不要全面抵抗呢?该怎么通过饮食来抵抗炎症呢?

Immunity:“一线”药物抗炎的背后

糖皮质激素(GC)具有抗炎、抗过敏、抗毒、抗休克等作用,是临床上的常用药物,更是多种急、慢性炎症治疗的一线用药。但是,其抗炎作用背后的机制仍未明确。